NECBB Perlish Story New England Cord Blood Bank. Stem cell cord blood banking testimony. By: NECordBloodBank … Continue reading →

Treatment for retinitis pigmentosa's The August 2 implant by second side is the name of the device. By: Mark Hughes … Continue reading →

Stem Cell Center By: coolkemme3 … Continue reading →

Cambridge researchers have developed a new method to produce stem cells using designed proteins. Stem cells have the potential to be used to replace dying or damaged cells with healthy cells. This repair could have wide-ranging uses in medicine such as organ replacement, bone replacement and treatment of neurodegenerative diseases. This study brings closer to realising the full potential of stem cell technology. We have gone down a completely different road to standard practices to produce stem cells from adult cells, says Dr Pentao Liu, senior author from the Wellcome Trust Sanger Institute. Current techniques to reprogramme cells are inefficient and its imperative to find other ways to create stem cells. We hope that our novel approach to reprogramming cells into stem cells will become a new and safer alternative to current practices. The team looked at proteins called transcription factors, which regulate the activity of all human genes. Each transcription factor acts to modify the activity of several or many genes. A key set of these transcription factors are able to convert or reprogramme adult cells into induced pluripotent stem cells or iPS cells. However, these factors also act on many genes other than those involved in reprogramming. The … Continue reading →

SynGen Inc., the midtown Sacramento medical device startup that develops stem cell harvesting systems, announced today that it has received U.S. Food and Drug Administration clearance to market three related products to process cord blood. All three products are related to the company's SynGenX-1000 system, which harvests stem and progenitor cells from units of collected cord blood. The company says harvested cells can be used for treatment of numerous medical conditions, including leukemia, lymphoma and more than 70 genetic diseases. "We thank the FDA for guiding us through the ... clearance process. SynGen is dedicated to developing products that consistently exceed our customers' expectations," said Philip Coelho, company president and CEO. Last year, SynGen received $5 million from San Francisco venture capital firm Bay City Capital LLC to further develop what Coelho has called the next generation in stem cell harvesting systems. SynGen recently received additional financing of up to $3 million from Bay City. Noting the new financing, Coelho said "we look forward to providing U.S. cord blood banks with the competitive advantage they will enjoy by using our products." The Sacramento company also said it has received certification to market products in Europe. SynGen's focus is the development … Continue reading →

Ten patients suffering from retinitis pigmentosa have had their eyesight restoredincluding a woman who had only 17 percent of her vision left By Anne A. Jambora Philippine Daily Inquirer MANELLE Jose (left) whose vision has been restored. Dr. Harvey Uy is part of a three-man team that tested stem cell therapy for vision restoration in retinis pigmentosa. ROMY HOMILLADA Making the blind see may no longer be an outrageous feat encountered only in books. What was once labeled a miracle is now the subject of intense study by the scientific community. The key to restoring vision? Why, yes, stem cell therapy, of course. The stem cell therapy that began in November 2011, while still limited to the cure of the inherited eye disease retinitis pigmentosa (RP), has already restored the eyesight of 10 subjects. RP is a degenerative disease that has, until today, no known cure. It is the most common inheritable cause for blindness1.5 million people around the world are blind from it. RP is a group of hereditary eye disorders that affects the retinas ability to respond to light, causing people to slowly lose their vision until they go completely blind. For most people afflicted with RP, when … Continue reading →

Stem cell therapy results in dramatic decrease in blood sugar, improved sleep, increased energy levels and shoulder mobility, and improved libido. But StemGenics says patients must be tested first if theyre up to it By Marge C. Enriquez Philippine Daily Inquirer OPERATION room maintains hospital standards. Sam Fernandez (not his real name), a businessman in his late 50s, who underwent stem cell treatment, excitedly called his doctor, about its immediate effects. Although the benefits were supposed to be visible six to eight weeks after the procedure, the patient felt like a young man again in six days. His doctor gave him intravenous therapy, directly injecting stem cell on the shoulder to address the chronic pains and the penis for erectile dysfunction. Aside from the dramatic decrease in blood sugar, improved sleep, increased energy levels and shoulder mobility, the patient reported increased libido. He claimed he was getting woody (slang for erection) every day that his wife couldnt keep up with him. As the age management medicine trend, there are many hospitals and aesthetic centers offering stem cell treatment at the average price of P1.2 to P1.4 million. Accredited by the Department of Health, StemGenics not only offers medical technology that … Continue reading →

Public release date: 15-Jul-2013 [ | E-mail | Share ] Contact: Jim Feuer jim.feuer@cchmc.org 513-636-4656 Cincinnati Children's Hospital Medical Center A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex (TSC) a genetic disease characterized by benign tumors on multiple organ systems. TSC is estimated to affect more than a million individuals throughout the world. The study is the latest to demonstrate the effectiveness of everolimus for TSC patients. Previous studies conducted at Cincinnati Children's Hospital Medical Center showed that everolimus reduced tumors in the brain and the kidney. The newest study, led by a physician-scientist at Cincinnati Children's in collaboration with a team at Texas Children's Hospital in Houston, has been accepted by the journal Annals of Neurology, and is available online. "Everolimus treatment reduced seizure frequency and duration in the majority of TSC epilepsy patients whose seizures previously did not respond to treatment," says Darcy Krueger, MD, PhD, a pediatric neurologist at Cincinnati Children's and lead author of the study. "This improvement in seizure control was associated with a better quality of life, and side effects were limited. Work is already underway to … Continue reading →

Park City, Utah, July 15 2013 (eTeligis via Accesswire) -- AurimMed Pharma, Inc. has been awarded the prestigious Epilepsy Innovation Seal of Excellence by the Epilepsy Foundation of America. This inaugural award recognizes AurimMed's innovative R&D strategy and its portfolio of novel, proprietary products targeted for the treatment of central nervous system (CNS) disorders, particularly epilepsy. AurimMed's principal lead drug candidate is designated AMP-X-0079. "AurimMed has the highest respect for the Epilepsy Foundation and its leadership. We are pleased that they recognize our proprietary Privileged Structure Platform and our work towards the development of AMP-X-0079 for the treatment of epilepsy. This Award is an important and significant milestone in the evolution of AurimMed Pharma and the development of AMP-X-0079", said Amir Pesyan, Chairman and CEO of AurimMed. "The AMP-X-0079 program has all the characteristics that we seek for the Epilepsy Innovation Seal of Excellence award," notes Roger J. Porter, MD, Chief Scientific Officer of the Epilepsy Foundation. "This potential drug has very impressive data from the NIH-NINDS screening program and has been created using a proven platform for success in other disease states." Philip M. Gattone, President and CEO of the Epilepsy Foundation, further stated, "This award is based on … Continue reading →